Citation

Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M. J. Child Adolesc. Psychopharmacol. 2019; 29(4): 313-317.

Affiliation

Genetics-Endocrine Center, Pediatrics, NYU-Winthrop University Hospital, Mineola, New York.

Copyright

(Copyright © 2019, Mary Ann Liebert Publishers)

DOI

10.1089/cap.2018.0102

PMID

30724590

Abstract

OBJECTIVE: To examine the role of Guanfacine Extended Release (GXR) in the management of behavioral disturbances in patients with Prader-Willi Syndrome (PWS).

METHODS: Twenty from a total of 27 individuals with genetically confirmed PWS, 6-26 years of age, with the following symptoms were identified: significant aggression/agitation, skin picking, and/or symptoms of attention-deficit/hyperactivity disorder (ADHD). Response to GXR for the above noted symptoms was categorized as improved, worsened, or unchanged, while assessing for side effects and tolerability.

RESULTS: Eleven of the 20 individuals reported skin-picking, 17 reported aggression/agitation, and 16 reported symptoms of ADHD. Nine (81.8%), 14 (82.3%), and 15 (93.7%) individuals showed an improvement in skin-picking, aggression/agitation, and ADHD, respectively, while on GXR treatment. Two patients with prior complaints of psychotic symptoms did not respond to GXR. Of note, no abnormal weight gain or significant adverse reaction was observed in this group, while on GXR.

CONCLUSIONS: In this study, GXR demonstrated improvement in symptoms of skin picking, aggression/agitation, and ADHD in patients with PWS. GXR was not effective in reducing psychosis or agitation related to psychotic symptoms. Future studies are warranted to further establish the utility of GXR in PWS patients.

Language: en

Keywords

Prader-Willi syndrome; aggression; guanfacine; hyperactivity; inattention; skin picking